Charles Herbaux

Patient-Reported Outcomes from Patients with Waldenström Macroglobulinemia Treated with Ibrutinib-Rituximab: Results from iNNOVATE Study

Purpose of the Study: For patients with Waldenström macroglobuli- nemia (WM), anemia and fatigue can impair quality of life. Ibrutinib is the only once-daily inhibitor of Brutons tyrosine...

Bernhard Hauns ;

Christian Buske ;

Steve Treon , MD, PhD, FRCP, FACP;

Veronique Leblond ;

Alessandra Tedeschi ;

Judith Trotman ;

Ramón García-Sanz ;

David Macdonald ;

Meletios-Athanasios Dimopoulos ;

Beatrice Mahe ;

Charles Herbaux ;

Leonard Heffner ;

Marzia Varettoni ;

M. Lia Palomba ;

Constantine S. Tam ;

Chaim Shustik ;

Jeffrey Matous , MD;

Efstathios Kastritis ;

Erik G. Poulsen ;

10/23/2019

Patient-Reported Outcomes from Patients with Waldenström Macroglobulinemia Treated with Ibrutinib-Rituximab: Results from iNNOVATE Study

Purpose of the Study: For patients with Waldenström macroglobuli- nemia (WM), anemia and fatigue can impair quality of life. Ibrutinib is the only once-daily inhibitor of Brutons tyrosine...

Erik G. Poulsen ;

Bernhard Hauns ;

Christian Buske ;

Steve Treon , MD, PhD, FRCP, FACP;

Veronique Leblond ;

Alessandra Tedeschi ;

Judith Trotman ;

Ramón García-Sanz ;

David Macdonald ;

Meletios-Athanasios Dimopoulos ;

Beatrice Mahe ;

Charles Herbaux ;

Leonard Heffner ;

Marzia Varettoni ;

M. Lia Palomba ;

Constantine S. Tam ;

Chaim Shustik ;

Jeffrey Matous , MD;

Efstathios Kastritis ;

10/23/2019

Featured CME Course

Targeted Therapies for the Management of Chronic Lymphocytic Leukemia: Evaluating the Evidence to Optimize Patient Care and Outcomes

Upcoming Events

February 2 ⁠–⁠ February 5

February 7 ⁠–⁠ February 9

February 27 ⁠–⁠ March 1

DCLF

March 17 ⁠–⁠ March 19

March 22 ⁠–⁠ March 23

NP Institute

March 27 ⁠–⁠ March 30

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

April 30 ⁠–⁠ May 4

WoundCon

May 1 ⁠–⁠ May 3

See Full Calendar